Karachi: Drug Regulatory Authority of Pakistan (DRAP) recently issued a notification to recall all the stocks of medicines as they were ‘posing a safety risk to patients.”
The drugs were recalled on a voluntary basis due to potential mix-up by the manufacturing authorities, WS GSK Consumer healthcare Pakistan Limited, Jamshoro.
The Product named, Azomax 500mg FCT, batch no.LJ2L manufactured by WS GSK Consumer healthcare Pakistan Limited was
found to have potential mix-up and hence was appealed by Novartis Pharma Limited, KARACHI before regulatory authority to voluntarily recall medicines.
An official document released by DRAP read that manufacturers should alert their sales officers/suppliers/ distributors to issue instructions to the pharmacies/hospitals, point of sales/purchase/use for the return of suspected stocks of product in question. “Furthermore, you are directed to submit a compliance report of recall to this division within seven (07) days positively,” the notification read.